Cellectar Biosciences Stock: $140 Million Deal Puts Iopofosine FDA Filing in Focus

Cellectar Biosciences on Tuesday secured up to $140 million in new funding and rolled out fresh 12-month results for its iopofosine I 131 program, giving the cancer drug maker a shot of cash for a planned confirmatory trial and a potential U.S. submission in Waldenström macroglobulinemia. The company pegged the overall response rate at 83.6% from its Phase 2b CLOVER WaM trial, targeting this rare blood cancer.

NASDAQ:CLRB · Stock Market
Follow on Google News
Add as preferred source Open in Google News

US Stock Market Today Updates

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 Strong Buy

NVIDIA

94/100
#2 Strong Buy

Meta Platforms

89/100
#3 Buy

Alphabet

87/100
#4 Buy

Amazon

84/100
#5 Selective Buy

Microsoft

80/100
View full portfolio
Editorial model selection. Not personalised advice.
MARKET CALENDAR

Key Events Today

The catalysts most likely to move markets.

#1

Warsh at Jackson Hole

Policy tone can move rates, USD, equities, gold and crypto simultaneously.

#2

Michigan sentiment

A weak final reading or elevated inflation expectations could pressure risk assets.

#3

Chicago PMI

A surprise versus 58.0 may alter the near-term manufacturing-growth narrative.

View full calendar
Times and estimates may change. Verify before trading.